Compare Funko Inc (FNKO) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Funko Inc vs Gilead Sciences, Inc. — how do they compare? Funko Inc trades at $5.74 (market cap $315.21M), while Gilead Sciences, Inc. trades at $134.79 (market cap $163.51B). The key difference: Gilead Sciences, Inc. is far larger — about 518.7× Funko Inc's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Funko Inc pays none. Which is the better fit depends on your goals.
| FNKO | GILD | |
|---|---|---|
Market Cap | $315.21M | $163.51B |
Sector | Consumer Staples | Health |
52-Week High | $5.88 | $155.80 |
52-Week Low | $2.46 | $108.22 |
Enterprise Value | $560.25M | $178.05B |
Dividend Yield | — | 2.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FNKO trades at $5.785, up 4.23% today, with a bullish technical signal from moving averages. The stock shows improving revenue trends, with Q1 2026 sales reaching $200.9M, beating expectations, though net income remains negative. Analyst consensus is split between Buy and Hold, with no Sell ratings. Recent news highlights new product launches and strong collectibles demand, supporting a positive sentiment shift.
Outlook: FNKO presents a speculative opportunity with recent earnings beats and revenue growth, but risks include persistent net losses and high debt. Investors should weigh the bullish technicals and product momentum against fundamental weaknesses in profitability and cash flow volatility.
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Funko Inc
Funko Inc is a US-based pop culture consumer products company. It creates whimsical, fun, and different products which enable the customer to express their affinity for their favorite through movie, TV show, video game, musician or sports team. The company holds licenses and the rights to create tens of thousands of characters including Game of Thrones, Walking Dead, Disney, Marvel, Harry Potter, Fallout, and others. Its products include Pop, Dorbz, Mystery Vinyl, Plush, Action Figures, and Others. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites.
Read more on FNKO →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
